AngioDynamics Receives FDA Approval for NanoKnife BPH Study

The U.S. Food and Drug Administration has granted AngioDynamics an Investigational Device Exemption to commence the RELIEF feasibility study. This research will evaluate the NanoKnife IRE platform as a minimally invasive treatment for benign prostatic hyperplasia (BPH). The approval marks a step forward in exploring new therapeutic options for this condition.